News from Antibody Solutions

Antibody Solutions + Single Cell Technology, Inc. Partnership Expands Access to Single B-Cell Antibody Discovery
New offering aims to advance researchers’ ability to develop broader repertoire of novel antibody candidates Sunnyvale, Calif. (Dec. 4, 2017) – Antibody Solutions, a leader in discovery of therap... ...more, comments
Roche Acquires Adheron Therapeutics and Lead Asset, SDP051
Adheron Therapeutics has been acquired by Roche in a deal worth up to $580 million. The lead asset, SDP051, a humanized monoclonal antibody targeting Cadherin-11, has completed Phase 1 of clinical dev... ...more, comments
Abs to Difficult Membrane Proteins
"Antibody Development Strategies for Difficult Membrane Proteins" will be presented by Dr John Kenney at the Discovery On Target meeting in Boston, Sept. 24, 2015 at 12:50 PM, Westin Boston Waterfront... ...more, comments
AAPS-NBC 2015 Exhibit Hall Pass
We are exhibiting at the AAPS National Biotech Conference June 8th and 9th at the Marriott Marquis in San Francisco. See below for the registration link and Promo Code for a free one-day conference... ...more, comments
Antibody Solutions to Attend AAPS National Biotechnology Conference
Antibody Solutions will be attending the AAPS National Biotechnology Conference, June 8-10, 2015 at the San Francisco Marriott Marquis. ...more, comments


News-Medical.Net Antibodies News Feed

Latest Antibodies News and Research

The outcome of viral myocarditis is closely associated with the immune response of the affected individual. An inhibitor of the immunoproteasome, a protein degradation complex in immunocompetent cells, reduces the extent of the inflammation and thus also the damage to the heart during myocarditis.
Posted: February 22, 2018, 4:49 pm
Substance abuse, particularly opioid abuse, is an ongoing issue in the U.S. While treatments such as drug counseling and a handful of medications to combat withdrawal symptoms and cravings exist, the fear and risk of relapsing is real.
Posted: February 22, 2018, 3:43 am
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, causes lethal respiratory paralysis within several years of diagnosis. There are no effective treatments to slow or halt this devastating disease.
Posted: February 21, 2018, 5:53 pm
AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.
Posted: February 20, 2018, 2:28 pm
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.
Posted: February 20, 2018, 8:58 am
A new blood test called the Tick-Borne Disease Serochip (TBD Serochip) promises to revolutionize the diagnosis of tick-borne disease by offering a single test to identify and distinguish between Borrelia burgdorferi, the pathogen responsible for Lyme disease, and seven other tick-borne pathogens.
Posted: February 19, 2018, 4:46 am
Lab mice injected with inactivated induced pluripotent stem cells (iPSCs) displayed a significant immune response against lung, breast, and skin cancers. The vaccine also prevented relapses in animals with removed tumors.
Posted: February 16, 2018, 2:24 pm
Dr. Castro is a translational oncologist with experience developing and harnessing nanotechnology and molecular imaging platforms for cancer purposes. His work offers a “less is more” approach — to generate robust cancer analyses using scant amount of specimens. Dr. Castro’s research has included funding from the V Foundation for Cancer Research, National Institutes of Health, Ovarian Cancer Research Fund, and the Department of Defense.
Posted: February 14, 2018, 9:59 am
In one of the first successes of its kind, researchers from Case Western Reserve University School of Medicine and six other institutions have inhibited the spreading of cancer cells from one part of the body to another.
Posted: February 13, 2018, 3:07 am
The TAT 2018 Honorary Award for cancer drug development has been granted to Professor Jean-Charles Soria, for his pioneering role in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy.
Posted: February 13, 2018, 2:39 am